Cartesian Therapeutics (RNAC) said Friday it enrolled the first participant in its phase 3 myasthenia gravis study that will evaluate Descartes-08, the company's lead cell therapy candidate for autoimmune disease.
The study will evaluate Descartes-08 versus placebo given as six once-weekly outpatient infusions without preconditioning chemotherapy in about 100 participants who have acetylcholine receptor autoantibody positive myasthenia gravis, the company said.
The trial's primary endpoint will assess the proportion of participants with an improvement in myasthenia gravis activities of daily living score of at least three points at month four compared with placebo, the company added.
Price: 9.63, Change: -0.37, Percent Change: -3.70
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。